Executive Summary The pharmaceutical company Merck has traditionally sold medicines and products that have been developed through its internal research. So, it is not surprising to see that the company spends quite a large amount of money on research. This is reflected in its financial statement as given in the exhibit 1. The R&D expenditure is about 7% of Merck's revenues. The life cycle of a drug takes it from the research labs to three phases of testing, each increasingly complex, then through
Words: 1229 - Pages: 5
Should Merck license the compound? Merck would be responsible for 1) the approval of Davanrik 2) the manufacture of Danavrik 3) marketing of Danavrik Merck would pay LAB for 1) initial fee 2) royalty on all sales 3) make additional pymts as Danavrik completed each stage of approval process (3 Phases) Additional facts: approval process should take 7 years patent will cover 17 years (7 of approval process nad 10 yr period of exclusivity beginning in yr 7) 1 Assumptions: All Cash flows
Words: 1029 - Pages: 5
TEACHING NOTE – Adapted From Harvard Business School MERCK & COMPANY: Evaluating a Drug Licensing Opportunity Substantive Issues The case explores the valuation of an opportunity to license a compound before it enters clinical trials and describes Merck’s decision tree evaluation process. It also provides information to evaluate a specific licensing opportunity, including the costs of the three phases of the review process, the present value of the revenues associated with successful
Words: 521 - Pages: 3
pay any tax on profits made overseas and are also exempt from paying any tax on profit made on cargo uplifted from Hong Kong. 5. What do you think of the company’s policy of not operating ships over 15 years old? Case #3: Merck & Company Questions 1. How has Merck been able to achieve substantial returns to capital given the large costs and
Words: 947 - Pages: 4
FINA 6092 Advanced Financial Management 2014-15 Term 1 Case questions Case #A: Butler Lumber Company Questions 1. Why does Mr. Butler have to borrow so much money to support this profitable business? 2. Do you agree with his estimate of the company’s loan requirements? How much will he need to borrow to finance his expected expansion in sales (assume a 1991 sales volume of $3.6 million)? 3. As Mr. Butler’s financial advisor, would you urge him to go ahead with, or to reconsider, his anticipated
Words: 1115 - Pages: 5
Executive Summary The pharmaceutical company Merck has traditionally sold medicines and products that have been developed through its internal research. So, it is not surprising to see that the company spends quite a large amount of money on research. This is reflected in its financial statement as given in the exhibit 1. The R&D expenditure is about 7% of Merck’s revenues. The life cycle of a drug takes it from the research labs to three phases of testing, each increasingly complex, then through
Words: 3097 - Pages: 13
#NAME? #NAME? Depression Don't Test #NAME? -$40,000,000.00 Indications #NAME? #NAME? 0 #NAME? #NAME? Test Effective #NAME? -$150,000,000.00 #NAME? 75.0% -100,000,000 #NAME? #NAME? Test Merck Decision Tree Although a decision analysis would recommend that Merck not commit to the proposal, the company's balance sheet shows that it has significant assets to support a loss. The projected values of earning for depression and dual indications seem to be worth the risk. Weightloss
Words: 354 - Pages: 2
UNIVERSITY OF WASHINGTON Graduate School of Business Administration Finance 553 CAPITAL INVESTMENT PLANNING Winter 2003 Professor Robert C. (Rocky) Higgins 306 Mackenzie Hall Tel: 543-4379 E-mail: rhiggins@u.washington.edu Homepage: http://us.badm.washington.edu/higgins/ (From here you’re one click from the class page) Office Hours: M, W: 10:30 – 12:00 COURSE OBJECTIVE Capital Investment Planning is a case course examining corporate investment decisions and related issues in
Words: 3270 - Pages: 14
Industry & Competitor Analysis BUS 630 – Spring 2008 Instructor: Email: Office Hrs: Course page: Russell Coff (www.bus.emory.edu/rcoff/) Russ_Coff@bus.emory.edu by appointment www.bus.emory.edu/rcoff/Bus630.html Phone: (404) 727-0526 FAX: (404) 727-6313 Revised 1/22/08 Course Overview and Objectives This course delves deeper into some strategy topics that you may have only touched upon earlier related to how firms gain a competitive advantage over rivals. In addition, since ICA tends to integrate
Words: 7898 - Pages: 32
